March 8
Meet Proxima Bio: Australia’s next-generation biotech startup aiming to clean up cancer-causing proteins.
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectThe Hunter Medical Research Institute (HMRI) is NSW’s second largest medical research institute. Its pioneering partnership with the University of Newcastle and Hunter New England Local Health District delivers key translational research outcomes and technology closely aligned to community health needs. More than 1400 clinical and biomedical researchers and support staff are employed across seven HMRI Research Programs, striving to prevent, cure and treat a diverse range of serious illnesses.
ViewThe ithree institute brings together a team of scientists with diverse skill sets who collectively address key challenges in the understanding and control of infectious diseases in humans and animals. Our senior scientists have recently refined the key research themes under which they will work together to increase their impact in the antibiotic resistance, food safety and infectious disease space.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreMeet Proxima Bio: Australia’s next-generation biotech startup aiming to clean up cancer-causing proteins.
Read moreCombination of First-in-Class Systemic TLR2/6 Agonist and Anti-PD-1 Monoclonal Antibody to be Studied in Patients with Advanced Solid Tumours
Read moreENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research
Read moreENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults
Read more